Dr Rajeev Singh Raghuvanshi has joined as the Secretary-cum-Scientific Director of the Indian Pharmacopoeia Commission (IPC) on February 16, 2021.
Dr Raghuvanshi’s expertise lies in dosage form design and development, majorly in pharma innovation. He has been involved in the development of different kind of products like Oral Solids, Oral liquids, Topicals, Injections, Nasal Sprays, Auto-injectors, Sublingual, Mouth Dissolve, Extended Release and Delayed Release for global markets. Dr Raghuvanshi has 14 granted US patents along with more than 250 published PCTs and Indian Patents. He has more than 25 publications in peer-reviewed journals and has co-authored six chapters in books. He has been visiting faculty at NIPER – Hyderabad and IIT-BHU and has taught students of NIPER-Mohali.
He has been working at Dr Reddy’s Laboratories since 2010. In his 11 years of stay with Dr Reddy’s Labs, the initial eight years was in development of 505b(2) NDA products for the US market. Last three years at Dr Reddy’s has been in a different role of establishing an R&D team for markets like India, China, Russia and other Emerging Markets in the space of Pharmaceutical Product Innovation/ Differentiation, registration and launches.
He has completed his Bachelors and Masters from IIT-BHU (Formerly IT-BHU), Varanasi and PhD from National Institute of Immunology, New Delhi. His PhD work is in the area of extended-release formulation of vaccines, a project conceptualised to help reduce the number of injections required to be given for complete immunisation.